

# **Bibliographie Cannabis et Cannabinoïdes en Neurologie**

***Docteur Christian SUEUR, GRECC, avril 2020.***

Cannabinoïdes et Sclérose en Plaque, p 4.

Cannabinoïdes et Migraines, p 7.

Cannabinoïdes et maladies neurodégénératives, p 8.

Cannabinoïdes et Maladie de Parkinson, p 10.

Cannabinoïdes et Maladie de Huntington, p 11.

Cannabinoïdes et Maladie d'Alzheimer, p 12.

1. AHMED A.I., van den ELSEN G.A., COLBERS A., KRAMERS C., BURGER D.M., van der MARCK M.A., OLDE RIKKERT M.G. : Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia, *Psychopharmacology (Berl)*, 2011, 229, 263-264.
2. BENBADIS S.R., SANCHEZ-RAMOS J., GIARRATANO M., KALIDAS K., KATZIN L., ROBERTSON D., VU T., SMITH A., ZESIEWICZ T. : Medical marijuana in neurology, *Expert Review of Neurotherapeutics*, 2014, 14, (12), 1453-1465.  
Doi : 10.1586/14737175.2014.985209
3. BLAKE D.R., ROBSON P., HO M., JUBB R.W., McCABE C.S. : Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis, *Rheumatology (Oxford)*, 2006, 45, 50-52.
4. BROERS B., PATÀ Z., MINA A., WAMPFLER J., de SAUSSURE C., PAUTEX S. : Prescription of a THC/CBD-Based Medication to Patients with Dementia : A Pilot Study in Geneva, *Medical Cannabis and Cannabinoids*, 2019, 2, 56-59.
5. CAVANAUGH J.R. : Medical Cannabis and Brain Disorders, *The American Alliance for Medical Cannabis, AAMC Pool Summary*, 2002.
6. CONSROE P., SANDYK R. : Potential role of cannabinoids for therapy of neurological disorders, In: Murphy, L., Bartke, A. (Eds.), "Marijuana/Cannabinoids : Neurobiology and Neurophysiology", CRC Press, Boca Raton, 1992, 459-524.
7. CONSROE P. : Brain Cannabinoid systems as targets for the therapy of neurological disorders, *Neurobiological Diseases*, 1998, 5, 534-541.
8. CREAN R.D., CRANE N.A., MASON B.J. : An evidence based review of acute and long-term effects of cannabis use on executive cognitive function, *Journal of Addiction Medicine*, 2011, 5, 1-8.
9. CROXFORD J.L. : Therapeutic potential of cannabinoids in CNS disease, *CNS Drugs*, 2003, 17, (3), 179-202.  
Doi : 10.2165/00023210-200317030-00004
10. De PETROCELLIS L., LIGRESTI A., MORIELLO A.S. et al. : Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endo-cannabinoid metabolic enzymes, *British Journal of Pharmacology*, 2011, 163, 1479-1494.

11. Di MARZO V, MELCK D., BISOGNO T et al. : Endocannabinoids : endogenous cannabinoid receptor ligands with neuro-modulatory action, *Trends in Neurosciences*, 1998, 21, 521-528.
12. GAMBI F., de BERARDIS D., SEPEDE G., QUARTESAN R., CALCAGNI E., SALERNO R.M., FERRO F.M. : Cannabinoid receptors and their relationships with neuropsychiatric disorders, *International Journal of Immunopathology and Pharmacology*, 2005, 18, 1, 5 p.
13. GIACOPPO S., GALUPPA M., POLLASTRO F., GRASSI G., BRAMANTI P., MAZZON E. : A new formulation of cannabidiol in creams shows therapeutic effects in a mouse model of experimental autoimmune encephalomyelitis, *Daru*, 2015, 23, 48.
14. GOTTSCHLING S., MÜLLER S., THEURER J. et al. : Dronabinol bei schwerst-mehrfach-behinderten Kindern mit Spastik, Schmerzen und Unruhe, *Palliativmedizin*, 2014, 15.
15. HAGENBACH U., LUZ S., BRENNISEN R., MADER M. : The treatment of spasticity with D9-tetrahydrocannabinol (D9-THC) in patients with spinal cord injury. *Paper presented at : IACM 2nd Conference on Cannabinoids in Medicine; September 12-13, 2003, Cologne, Germany.*
16. HARRIS H.M., SUFKA K.J., GUL W., ELSOHLY M.A. : Effects of Delta-9-Tetrahydro-cannabinol and Cannabidiol on Cisplatin-Induced Neuropathy in Mice, *Planta Medica*, 2016, 82, (13), 1169-1172.
17. HILL A.J., WILLIAMS C.M., WHALLEY B.J., STEPHENS G.J. : Phytocannabinoids as novel therapeutic agents in CNS disorders, *Pharmacology & Therapeutics*, 2012, 133, (1), 79-97.  
Doi : 10.1016/j.pharmthera.2011.09.002v
18. IANNOTTI F.A., Di MARZO V., PETROSINO S. : Endocannabinoids and endocannabinoid-related-mediators : Targets, metabolism and role in neurological disorders, *Progress in Lipid Research*, 2016, 62, 107-128.
19. IANNOTTI F.A., PISCITELLI, F. MARTELLA A., MAZZARELLA E., ALLARÀ M., PALMIERI V., PARRELLA C., CAPASSO R., Di MARZO, V. : Analysis of the "endocannabinoidome" in peripheral tissues of obese Zucker rats, *Prostaglandins, Leukotrienes and Essential Fatty Acids*, 2013, 89, 127-135.
20. IBEAS BIH C., CHEN T. NUNN A.V., BAZELOT M., DALLAS M., WHALLEY B.J. : Molecular Targets of Cannabidiol in Neurological Disorders, *Neurotherapeutics*, 2015, 12, 4, 699-730.  
Doi : 10.1007/s13311-015-0377-3
21. KOPPEL B.S., BRUST J.C., FIFE T. et al. : Systematic review : efficacy and safety of medical marijuana in selected neurologic disorders : report of the Guideline Development Subcommittee of the American Academy of Neurology, *Neurology*, 2014, 82, 1556-1563.
22. KOVACS F.E., KNOP T., URBANSKI M.J. et al. : Exogenous and endogenous cannabinoids suppress inhibitory neurotransmission in the human neocortex, *Neuropsychopharmacology*, 2012, 37, 1104-1114.
23. MANERA C., ARENA C., CHICCA A. : Synthetic cannabinoid receptor agonist and antagonists : implication in CNS disorders, *Recent Patents on CNS Drug Discovery*, 2015, 10, 2 142-156.
24. MANNUCCI C., NAVARRA M., CALAPAI F. et al. : Neurological Aspects of Medical Use of cannabidiol, *CNS & Neurological Disorders – Drug Targets*, 2017, 16, 13 pp.

25. PETRO D.J.: Chapter 9: Spasticity and chronic pain, In : Mathre, M.L. (Ed.), *Cannabis in Medical Practice. A Legal, Historical, and Pharmacological Overview of the Therapeutic Use of Marijuana*, McFarland and Co., Jefferson, 1997, 112-124.
26. ROSENBERG E.C., TSIEN R.W., WHALLEY B.J. , DEVINSKY O. : Cannabis and epilepsy, *Neurotherapeutics*, 2015, 18, 747-768.
27. SCUDERY C. ET AL. : Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders, *Phytotherapy Research*, 2009, 23, (5), 597-602.  
Doi : 10.1002/ptr.2625
28. SCHURMAN L.D., LICHTMAN A.H. : Endocannabinoids : A Promising Impact for Traumatic Brain Injury, *Frontiers in Pharmacology*, 2017, Vol 8, Article 69, 17 p.  
Doi : 10.3389/fphar.2017.00069
29. SOLIMINI R., ROTOLI M.C., PICHINI S. et al. : Neurological disorders in medical use of Cannabis : An update, *CNS Neurological Disorders-Drug Targets*, 2017, 16, 527-533.
30. WADE D.T., ROBSON P.J., HOUSE H., MAKELA P.M., ARAM J. : A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms, *Clinical Rehabilitation*, 2003, 17, 21-29.
31. WILSON R.I., NICOLL R.A. : Endocannabinoid signaling in the brain, *Science*, 2002, 296, 678, 682.

## Cannabinoïdes et Sclérose en Plaque

1. AKGÜN K., ESSNER U., SEYDEL C., ZIEMSEN T. : Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol : Cannabidiol Oromucosal Spray : A Systematic Review of Observational Studies, *Journal of Central Nervous System Disease*, 2019, 11, 1-18.  
Doi : 10.1177/1179573519831997
2. BAKER D., PRYCE G., CROXFORD J.L., BROWN P., PERTWEE R.G., HUFFMAN J.W. et al. : Cannabinoids control spasticity and tremor in multiple sclerosis model, *Nature*, 2000, 404, 84-87.
3. BUCCELLATO E., CARRETTA D., UTAN A., CAVINA C., SPERONI E., GRASSI G., CANDELETTI S., ROMUALDI P. : Acute and chronic cannabinoid extracts administration affects motor function in a CREAE model of multiple sclerosis, *Journal of Ethnopharmacology*, 2011, 133, (3), 1033-1038.  
Doi : 10.1016/j.jep.2010.11.035
4. CHIURCHIÙ V., Van der STELT M., CENTONZE D., MACCARRONE M. : The endocannabinoid system and its therapeutic exploitation in multiple sclerosis : Clues for other neuroinflammatory diseases, *Progress in Neurology*, 2018, 160, 82-100.
5. CLIFFORD D.B. : Tetrahydrocannabinol for tremor in multiple sclerosis, *Ann Neurol*, 1983, 13, 669-671.  
<https://www.ncbi.nlm.nih.gov/pubmed/6309074?dopt=Abstract>
6. CONSROE P., MUSTY R., REIN J., TILLERY W., PERTWEE R. : The perceived effects of smoked cannabis on patients with multiple sclerosis, *European Neurology*, 1997, 38, 1, 44-8.  
<https://www.ncbi.nlm.nih.gov/pubmed/9252798?dopt=Abstract>
7. Di MARZO , CENTONZE : Placebo effects in a multiple sclerosis spasticity enriched clinical trial with the oro-mucosal cannabinoid spray (THC/CBD) : dimension and possible causes, *CNS Neuroscience & Therapeutics*, 2015, 21, 3, 215-221.
8. GIACOPPO S., SOUNDARA RAJAN T., GALUPPO M., POLLASTRO F., GRASSI G., BRAMANTI P., MAZZON E. : Purified Cannabidiol, the main non-psychotropic component of Cannabis sativa, alone, counteracts neuronal apoptosis in experimental multiple sclerosis, *European Review for Medical and Pharmacological Sciences*, 2015, 19, 4906-4919.
9. GIACOPPO S., POLLASTRO F., GRASSI G., BRAMANTI P., MAZZON E. : Target regulation of PI3K/Akt/mTOR pathway by cannabidiol in treatment of experimental multiple sclerosis, *Fitoterapia*, 2016, 116, 77-84.
10. KILLSTEIN J., HOOGERVORST E.L., REIF M., KALKERS N.F., VAN LOENEN A.C., STAATS P.G. et al. : Safety, tolerability, and efficacy of orally administered cannabinoids in MS, *Neurology*, 2002, 58, 1404-1407.  
<https://www.ncbi.nlm.nih.gov/pubmed/12011290?dopt=Abstract>
11. MALFITANO A.M., MATARESE G., BIFULCO M. : From cannabis to endocannabinoids in multiple sclerosis : a paradigm of central nervous system autoimmune diseases, *Curr Drug Targets CNS Neurol Disord*, 2005, 4, 6, 667-675.  
<https://www.ncbi.nlm.nih.gov/pubmed/16375684>

12. MARTYN C.N., ILLIS L.S., THOM J. : Nabilone in the treatment of multiple sclerosis, *Lancet*, 1995, 345, 579-579.  
<https://www.ncbi.nlm.nih.gov/pubmed/7776785?dopt=Abstract>
13. MEINCK H.M., SCHONLE P.W., CONRAD B. : Effect of cannabinoids on spasticity and ataxia in multiple sclerosis, *Journal of Neurology*, 1989, 236, 120-122.  
<https://www.ncbi.nlm.nih.gov/pubmed/2709054?dopt=Abstract>
14. MEUTH S.G., HENZE T., ESSNER U., TROMPKÉ C., VILA SILVAN C. : Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity : consistency of response across subgroups from the SAVANT randomized clinical trial, *International Journal of Neuroscience*, 2020.  
Doi : 10.1080/00207454.2020.1730832
15. NIELSEN S., GERMANOS R., WEIER M. et al. : The use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis : a systematic Review of Reviews, *Current Neurology and Neuroscience Reports*, 2018, 18, 8, 12 pp. DOI : 10.1007/s11910-018-0814-x
16. PERTWEE R.G. : Cannabinoids and multiple sclerosis, *Pharmacology & Therapeutics*, 2000, 95, 2, 165-174.  
<https://www.ncbi.nlm.nih.gov/pubmed/12182963>
17. PETRO D.J., ELLENBERGER C. : Treatment of human spasticity with delta-9-THC, *Journal of Clinical Pharmacology*, 1981, 21, 413-416.  
<https://www.ncbi.nlm.nih.gov/pubmed/6271839?dopt=Abstract>
18. PETRO D.J. : Chapter 9: Spasticity and chronic pain, In : Mathre, M.L. (Ed.), *Cannabis in Medical Practice. A Legal, Historical, and Pharmacological Overview of the Therapeutic Use of Marijuana*, McFarland and Co., Jefferson, 1997, 112-124.
19. RAHIMI A., FAIZI M., TALEBI F., NOORBAKSH F., KAHRIZI F., NADERI N. : Interaction between the protective effects of cannabidiol and palmitoyl-ethanolamide in experimental model of multiple sclerosis in C57BL/6 Mice, *Neuroscience*, 2015, 290, 279-287.  
Doi : 10.1016/j.neuroscience.2015.01.030
20. SERPELL M.G., NOTCUTT W., COLLINS C. : Sativex long-term use an open-label trial in patients with spasticity due to multiple sclerosis, *Journal of Neurology*, 2013, 260, 285-295.
21. SMITH P.F. : Cannabinoids in the treatment of pain and spasticity in multiple sclerosis, *Current Opinion Investigational Drugs*, 2002, 3, 6, 859-864.  
<https://www.ncbi.nlm.nih.gov/pubmed/12137404>
22. TREBST C., STANGEL M. : Cannabinoids in multiple sclerosis - therapeutically reasonable ?, *Fortschr Neurol Psychiatr*, 2005, 73, 8, 463-9.  
<https://www.ncbi.nlm.nih.gov/pubmed/16052440>
23. UNGERLEIDER T., ANDYRSIAK T., FAIRBANKS L., ELLISON G.W., MYERS L.W. : Delta-9-THC in the treatment of spasticity associated with multiple sclerosis, *Advances in Alcohol & Substance Abuse*, 1987, 7, 39-50.  
<https://www.ncbi.nlm.nih.gov/pubmed/2831701?dopt=Abstract>
24. WADE D.T., MAKELA P., ROBSON P., HOUSE H., BATEMAN C. : Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients, *Multiple Sclerosis*, 2004, 10, 434-441.  
Doi : 10.1191/1352458504ms1082oa

25. WADE D.T., ROBSON P.J., HOUSE H., MAKELA P.M., ARAM J. : A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms, *Clin Rehab*, 2003, 17, 21-29.
26. ZAJICEK J., FOX P., SANDERS H., WRIGHT D., VICKERY J., NUNN A., THOMPSON A. on behalf of the UK MS research group : Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study) : multi-centre randomized placebo-controlled trial, *Lancet*, 2003, 362, 1517-1526.

## Cannabinoïdes et Migraines

1. BARON E.P. : Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache : What a Long Strange trip It's Been ...., *Headache*, 2015, 55, (6), 885-916.  
Doi : 10.1111/head.12570
2. CUTTLER C., SPRADLIN A., CLEVELAND M.J., CRAFT R.M. : Short-and Long-Term Effects of Cannabis on Headache and Migraine, *Journal of Pain*, 2019.  
Doi : 10.1016/j.jpain.2019.11.001
3. LOCHTE B.C., BELETSKY A., SAMUEL N. K., GRANT I. : The Use of Cannabis for Headache Disorders., *Cannabis and Cannabinoid Research*, 2017, 2 :1, 61-71.
4. MAPS : Cannabis in Migraine Treatment Study, 20 February 2000.  
[www.maps.org/research-archive//mmj/mjrusso.html](http://www.maps.org/research-archive//mmj/mjrusso.html)
5. McGEENEY B.E. : Cannabinoids and hallucinogens for headache, *Headache*, 2013, 53, 3, 447-458.
6. NAGY-GROCZ G., ZADOR F., DVORACSKO S., BOHAR Z., BENYHE S., TÖMBÖLY C., PARDUTZ A., VECSEI L. : Interactions between the Kynurenone and the Endocannabinoid System with Special Emphasis on Migraine, *International Journal of Molecular Sciences*, 2017, 18, 1617.  
Doi : 10.3390/ijms18081617
7. OLIVEIRA A.B., RIBEIRO R.T., MELLO M.T., TUFIK S., PERES M.F.P. : Anandamide is Related to Clinical and Cardiorespiratory Benefits of Aerobic Exercise Training in Migraine Patients : A Randomized Controlled Clinical trial, *Cannabis and Cannabinoid Research*, 2019, 4, (4), 275-284.  
Doi : 10.1089/can.2018.0057
8. RHYNE D.N., ANDERSON S., GEDDE M., BORGELT L.M. : Effects of Medical Marijuana on Migraine Headache Frequency in a Adult Population, *Pharmacotherapy*, 2016, 36, (5), 505-510.  
Doi : 10.1002/phar.1673
9. RUSSO E. : Cannabis for migraine treatment : the once and future prescription ? An historical and scientific review, *Pain*, 1998, 76, 3-8.
10. RUSSO E. : Hemp for Headache : An In-Depth Historical and Scientific Review of Cannabis in Migraine Treatment, *Journal of Cannabis Therapeutics* 2001, 12, 21-92.
11. RUSSO E.B. : Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes, *Cannabis and Cannabinoid Research*, 2016, 1, 1, 154-165. Doi : 10.1089/can.2016.0009

## Cannabinoïdes et maladies neurodégénératives

1. AGUILERA G., SANTAMARIA A.: Potential Therapeutic Targets of the Endocannabinoid System in Common Neurodegenerative Disorders and Organic Academias, *Journal of Inborn Errors of Metabolism & Screening*, 2017, 5, 1-9.  
Doi : 10.1177/2326409817723667
2. ALTAMURA C. et al. : Elevation of Plasma 2 -Arachidonoylglycerol Levels in Alzheimer's Disease Patients as a Potential Protective Mechanism against Neurodegenerative Decline, *Journal of Alzheimer Disease*, 2015, 46, 2, 497-506.
3. ASO E., SANCHEZ-PLA A., VEGAS-LOZANO, MALDONADO R., FERRER I.: Cannabis-based medicine reduces multiple pathological process in A $\beta$ PP/PS1 mice, *Journal of Alzheimer's Disease*, 2015, 43, 977-991.
4. ASO E. et al. : Delineating the Efficacy of a Cannabis-Based Medicine at Advanced Stages of Dementia in a Murine Model, *Journal of Alzheimer Disease*, 2016, 54, 3, 903-912.
5. BISOGNO T., ODDI S., PICCOLI A., FAZIO D., MACCARRONE M.: Type-2 cannabinoid receptors in neurodegeneration, *Pharmacological Research*, 2016, 111, 721-730.
6. BILKEI-GORZO A., ALBAYRAM O., DRAFFEHN A., MICHEL K., PIYANOVA A., OPPENHEIMER H., DVIR-GINZBERG M., RACZ I., ULAS T., IMBEAULT S., BAB I., SCHULTZE J.L., ZIMMER A.: A chronic low dose of  $\Delta$ 9-tetrahydrocannabinol (THC) restores cognitive function in old mice, *Nature Medicine*, 2017, 23, 782-787. DOI : 10.1038/nm.4311
7. BROERS B., PATÀ Z., MINA A., WAMPFLER J., de SAUSSURE C., PAUTEX S.: Prescription of a THC/CBD-Based Medication to Patients with Dementia : A Pilot Study in Geneva, *Medical Cannabis and Cannabinoids*, 2019, 2, 56-59.
8. FERNANDEZ-RUIZ J., GONZALES S., ROMERO J., RAMOS J.A.: Cannabinoids in neurodegeneration and neuroprotection, in « *Cannabinoids as Therapeutics* », Ed. R. Mechoulam, Birkhäuser Verlag, Switzerland, 2005, 79-109.
9. FERNANDEZ-RUIZ J., SAGREDO O., PAZOS R., GARCIA C., PERTWEE R., MECHOULAM R., MARTINEZ-ORGADO J.: Cannabidiol for neurodegenerative disorders : important new clinical applications for this phytocannabinoid ?, *British journal of Clinical Pharmacology*, 2012, 75, 2, 323-333.
10. FERNANDEZ-RUIZ J., ROMERO J., RAMOS J.A.: Endocannabinoids and Neurodegenerative Disorders : Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease and others, *Handbook of Experimental Pharmacology*, 2015, 231, 233-59.
11. FOX S.H., KELLETT M., MOORE A.P., CROSSMAN A.R., BROTCHIE J.M.: Randomized, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia, *Movement Disorders*, 2002, 17, 145-149.
12. FRIEDMAN D., FRENCH J.A., MACCARRONE M. : Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders, *Lancet Neurology*, 2019.  
Doi : 10.1016/S1474-4422(19)30032-8
13. HOUNIE A.G., ALMEIDA VASQUES M.A. : Neurological Improvement with Medical Cannabis in a Progressive Supranuclear Palsy Patient : A Case Report, *Medical Cannabis and Cannabinoids*, 2019, 2, 65-68.  
Doi : 10.1159/000503864

14. LIM K., SEE Y.M., LEE J. : A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative disorders, *Clinical Psychopharmacology and Neuroscience*, 2017, 15, 4, 301-312.
15. MACCARRONE M., BERNARDI G., FINAZZI AGRO A., CENTONZE D. : Cannabinoid receptor signaling in neurodegenerative diseases : a potential role for membrane fluidity disturbance, *British Journal of Pharmacology*, 2011, 163, 1379-1390. DOI : 10.1111/j.1476-5381.2011.01277.x
16. MANNUCCI C., NAVARRA M., CALAPAI F. et al. : Neurological Aspects of Medical Use of cannabidiol, *CNS & Neurological Disorders – Drug Targets*, 2017, 16, 13 pp.
17. MARTIN-MORENO A.M., BRERA B., SPUCH C. et al. : Prolonged oral cannabinoid administration prevents neuroinflammation, lowers  $\beta$ -amyloid levels and improves cognitive performance in Tg APP 2576 mice, *Journal of Neuroinflammation*, 2012, 9, 8, 15 pp.
18. MILTON N.G. : Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide, *Neuroscience Letters*, 2002, 332, 2, 127-130.
19. PASSMORE M.J. : The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation, *International Journal of Geriatric Psychiatry*, 2008, 23, 1, 116-117.
20. SAITO V.M., REZENDE R.M., TEIXEIRA A.L. : Cannabinoid Modulation of Neuroinflammatory Disorders, *Current Neuropharmacology*, 2012, 10, (2), 159-166 159.  
Doi : 10.2174/157015912800604515
21. SCOTTER E.L., ABOOD M.E., GLASS M. : The endocannabinoid system as a target for the treatment of neurodegenerative disease, *British Journal of Pharmacology*, 2010, 160, (3), 480-498.  
Doi : 10.1111/j.1476-5381.2010.00735.x
22. SHELEF A. et al. : Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An Open Label, Add-On, Pilot Study, *Journal of Alzheimer Disease*, 2016, 51, 1, 15-19.
23. WALTHER S., MAHLBERG R., EICHMANN U. et al. : Delta-9-tetrahydrocannabinol for night-time agitation in severe dementia, *Psychopharmacology (Berl)*, 2006, 185, 4, 524-528.
24. WOODWARD et al. : Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms, *American Journal of Geriatric Psychiatry*, 2014, 22, 4, 415-419.
25. ZIPP F., AKTAS O. : The brain as a target of inflammation : common pathways link inflammatory and neurodegenerative diseases, *Trends in Neurosciences*, 2006, 29, 518-527.

## Cannabinoïdes et Maladie de Parkinson

1. BALASH Y., BAR-LEV SCHLEIDER L., KORCZYN et al.: Medical Cannabis in Parkinson Disease : Real-Life Patients Experience, *Clinical Neuropharmacology*, 40, 6, 268-272.
2. CARROLL C.B., BAIN P.G., TEARE L. et al. : Cannabis for dyskinesia in Parkinson's disease : a randomized double-blind crossover study, *Neurology*, 2004, 63, 7, 1245-1250.
3. CHAGAS M.H., ZUARDI A.W., TUMAS V., PENA-PEREIRA M.A. et al. : Effects of cannabidiol in the treatment of patients with Parkinson's disease : an exploratory double-blind trial, *Journal of Psychopharmacology*, 2014, 28, 11, 1088-1098.
4. FOX S.H., HENRY B., HILL M. et al. : Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned non-human primate model of Parkinson's disease, *Movement Disorders*, 2002, 17, 6, 1180-1187.
5. FRANKEL J.P., HUGHES A., LEES A.J., STERN G.M. : Marijuana for Parkinsonian tremor, *Journal of Neurology, Neurosurgery and Psychiatry*, 1990, 53, 436.
6. GARCIA C., PALOMO-GARO C., GARCIA-ARENIBIA M., RAMOS J.A., PERTWEE R.G., FERNANDEZ-RUIZ J. : Symptom-relieving and neuroprotective effects of the phytocannabinoid delta9-THC in animal models of Parkinson's disease, *British Journal of Pharmacology*, 2011, 163, 1495-1506.  
DOI : 10.1111/j.1476-5381.2011.01278.x
7. GROtenhermen F. : Chanvre en Médecine. Redécouverte d'une plante médicinale. Guide pratique des applications thérapeutiques du Cannabis, du THC et du CBD, Edition Solanacée, 2017, « Maladie de Parkinson » p 102.
8. HA A.D., JANKOVIC J. : Pain in Parkinson's disease, *Movement Disorders*, 2012, 27, 4, 485-491.
9. LASTRES-BECKER I., MOLINA-HOLGADO F., RAMOS J.A., MECHOULAM R., FERNANDES-RUIZ J. : Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro : Relevance to Parkinson's disease, *Neurobiology of Diseases*, 2005, 19, 96-107.
10. LOTAN I. TREVES T.A., RODITI Y., DJALDETTI R. : Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease : an open-label observational study, *Clin Neuropharmacological*, 2014, 37, 2, 41-44.
11. MORE S.V., CHOI D.K. : Promising cannabinoid-based therapies for Parkinson's disease : motor symptoms to neuroprotection, *Molecular Neurodegeneration*, 2015, 10, 17.
12. PABON M.M., BACHSTETTER A.D., HUDSON C.E. et al. : CXCL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease, *Journal of Neuroinflammation*, 2011, 8, 9.  
[https://jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-9-8#Sec9\\_511](https://jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-9-8#Sec9_511)
13. SIERADZAN K.A., FOX S.H., DICK J., BROTCHE J.M. : The effects of the cannabinoid receptor agonist nabilone on L-DOPA induced dyskinesia in patients with idiopathic Parkinson's disease, *Movement Disorders*, 1998, 13 (suppl 2) 29.
14. SIERADZAN K.A., FOX S.H., HILL M., DICK J.P.R., CROSSMAN AR, BROTCHE J.M. : Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease : A pilot study, *Neurology*, 2001, 57, 2108-2111.

## Cannabinoïdes et Maladie de Huntington

1. CONSROE P. et al. : Controlled clinical trial of cannabidiol in Huntington's disease, *Pharmacology Biochemistry and Behavior*, 1991, 40, 3, 701-708.
2. LOPES-SENDON MORENO J.L., GARCIA CALDENTEY J. et al. : A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease, *Journal of Neurology*, 2016, 263, 7, 1390-1400.
3. SAFT C., Von HEIN S.M., LÜCKE T., THIELS C. et al. : Cannabinoids for Treatment of Dystonia in Huntington's Disease, *Journal of Huntington's Disease*, 2018, 7, 2, 167-173.
4. SAGREDO O., PAZOS M.R., SATTA V., RAMOS J.A., PERTWEE R.G., FERNANDEZ-RUIZ J.: Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease, *Journal of Neuroscience Research*, 2011, 89, (9), 1509-1518.  
Doi : 10.1002/jnr.22682
5. SAGREDO O., PAZOS M.R., VALDEOLIVAS S., FERNANDEZ-RUIZ J. : Cannabinoids : novel medicines for the treatment of Huntington's disease, *Recent Patent in CNS Drug Discovery*, 2012, 7, 1, 41-48.
6. VALDEOLIVAS S., SATTA V., PERTWEE R.G., FERNANDEZ-RUIZ J., SAGREDO O. : Sativex-Like Combination of Phytocannabinoids is Neuroprotective in Malonate-Lesioned rats, an Inflammatory Model of Huntington's Disease : Role of CB1 and CB2 Receptors, *ACS Chemical Neuroscience*, 2012, 3, 400-406.
7. VALDEOLIVAS S., SAGREDO O., DELGADO M. et al. : Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington's Disease, *International Journal of Molecular Sciences*, 2017, 18, 684, 12 pp.

## Cannabinoïdes et Maladie d'Alzheimer

1. ALTAMURA C. et al. : Elevation of Plasma 2 -Arachidonoylglycerol Levels in Alzheimer's Disease Patients as a Potential Protective Mechanism against Neurodegenerative Decline, *Journal of Alzheimer Disease*, 2015, 46, 2, 497-506.
2. ASO E., FERRER I. : Cannabinoids for treatment of Alzheimer's disease : moving toward the clinic, *Frontiers in Pharmacology*, 2014, 5, 37, 11 pp.
3. ASO E., FERRER I. : CB2 Cannabinoid Receptor as Potential Target against Alzheimer's Disease, *Frontiers in Neuroscience*, 2016, 10, article 243, 10pp.
4. ASO E., ANDRES-BENITO P., FERRER I. : Genetic deletion of CB1 cannabinoid receptors exacerbates the Alzheimer-like symptoms in a transgenic animal model, *Biochemical Pharmacology*, 2018, DOI : 10.1016/j.bcp.2018.08.007
5. BEDSE G., ROMANO A., LAVECCHIA A.M. et al. : The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer's disease, *Journal of Alzheimer's Disease*, 2015, 43, 4, 1115-1136.
6. CALABRESE E.J., RUBIO-CASILLAS A. : Biphasic effects of THC in memory and cognition, *European Journal of Clinical Investigation*, 2018, 48, e12920.  
Doi : 10.1111/eci.12920
7. CAMPBELL V.A. GOWRAN A. : Alzheimer's disease ; taking the edge off with cannabinoids ?, *British Journal of Pharmacology*, 2007, 152, 5, 655-662.  
Doi : 10.1038/sj.bjp.0707446
8. CURRAIS A., QUEHENBERGER O., ARMANDO A.M., DAUGHERTY D., MAHER P., SCHUBERT D. : Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids, *NPJ, Aging and Mechanisms of Disease*, 2016, 2, 16012.  
Doi : 10.1038/npjamd.2016.12
9. EUBANKS L.M., ROGERTS C.J. : A Molecular Link Between the Active Component of Marijuana and Alzheimer's Disease Pathology, *Molecular Pharmacology*, 2006, 3, 6, 773-777.  
Doi : 10.1021/mp060066m
10. GROTHENHERMEN F. : Chanvre en Médecine. Redécouverte d'une plante médicinale. Guide pratique des applications thérapeutiques du Cannabis, du THC et du CBD, Edition Solanacée, 2017, « Maladie d'Alzheimer » p 77.
11. HERRMANN N., LANCTOT K. : La marijuana pour la maladie d'Alzheimer ?, CCNV/CCNA,  
<http://ccna-ccnv.ca/fr/nouvelles/blogueurs-invites-la-marijuana-pour-la-maladie-dalzheimer>
12. JAYANT S. et al. : Pharmacological benefits of selective modulation of cannabinoid receptor type 2 (CB2) in experimental Alzheimer's disease, *Pharmacological and Biochemistry Behavior*, 2016, 140, 39-50.
13. KARL T., CHENG D., GARNER B., ARNOLD J.C. : The therapeutic potential of the endocannabinoid system for Alzheimer's disease, *Expert Opinion Therapeutic Targets*, 2012, 16, 4, 407-420.
14. MARTIN-MORENO et al. : Cannabidiol and Other Cannabinoids Reduce Microglial Activation In Vitro and in Vivo : Relevance to Alzheimer's Disease, *Molecular Pharmacology*, 2011, 79, 6, 964-973.
15. PATEL S., SHUA-HAIM J.R., PASS M. : Safety and efficacy of dronabinol in the treatment of agitation in patients with Alzheimer's disease with anorexia : A

- retrospective chart review, *Abstract 11th International Conference of the IPA*, 17-22 August 2003, Chicago.
- 16. RAMIREZ B.G., BLAZQUEZ C et al. : Prevention of Alzheimer's disease pathology by cannabinoids : neuroprotection mediated by blockade of microglial activation, *Journal of Neuroscience*, 2005, 23, 25, 8, 1904-1913.
  - 17. SHELEF A., BARAK Y., BERGER U., PALEACU D., TADGER S., PLOPSKY I., BARUCH Y. : Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia : An-Open Label, Add-On, Pilot Study, *Journal of Alzheimer's Disease*, 2016, 51, 1, 15-19.  
Doi : 10.3233/JAD-150915
  - 18. VOLICER L., STELLY M, MORRIS J. et al. : Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's Disease, *International Journal of Geriatric Psychiatry*, 1997, 12, 913-919.